Page 1229 - Adams and Stashak's Lameness in Horses, 7th Edition

Index 1195

metatarsus muscle soreness, 862–865 nuclear medicine, 447–448
see also metacarpus/metatarsus clostridial myositis, 864 radiography, 445–446
ultrasonography, 446–447
electrolyte disturbances, 864–865
VetBooks.ir dorsal aspect, 34–36 muscle abscesses, 864 etiology, 440–442
functional anatomy, 34–38
lateral and medial aspects, 36–38
muscle atrophy/denervation atrophy, 865
jumping/eventing/dressage, 991–992
prognosis, 453–454
plantar aspect, 38
muscle cramping, 864–865
nuclear medicine
endoscopy/bursoscopy, 453
abnormal conditions, 360, 361, muscle ischemia, 863–864 surgical treatments, 452–453
muscle trauma, 862–863
363–364 myogenic atrophy, 865 inferior check ligament desmotomy, 453
normal bone, 351, 351 overuse and muscle strain, 862 palmar digital neurectomy, 452–453
radiography, 263–267 muscle evaluation, ultrasonography, 333–334 treatment, 448–452
methocarbamol (Robaxin), 878 muscle injuries, thermography, 435–436 bisphosphonates: tiludronate or
methylprednisolone acetate (MPA), muscles of the trunk and neck, functional clodronate, 452
intrasynovial therapies, 887–888 anatomy, 63–64 corrective trimming and shoeing,
methylsulfonylmethane (MSM), musculoskeletal examination, prepurchase 449–451
nutraceutical, 906 examination (PPE), 1172 intrasynovial medication, 451–452
middle (second) phalanx (P2) musculoskeletal infections, 1153–1159 nonsteroidal anti‐inflammatory drugs
fractures, 522–525 clinical signs, 1153–1154, 1155 (NSAIDs), 451
clinical signs, 524 diagnosis, 1154–1155, 1156 polysulfated glycosaminoglycans
comminuted P2 fractures, 525 prognosis, 1159 (PSGAGs), 452
diagnosis, 524 regional antimicrobial delivery systems, rest and controlled exercise, 449
eminence fractures, 525 1156–1158 navicular wedge test, palpation and
etiology, 523–524 antibiotic‐impregnated materials, 1158 manipulation, 119–120, 121
osteochondral fractures, 524–525 intrasynovial antimicrobials, neck and poll, 796–799
prognosis, 525 1156–1157 cervical facet joints, 797–798
treatment, 524–525 regional limb perfusions, 1157–1158 clinical signs, 797
middle and proximal metatarsus, fracture treatment, 1155–1159 diagnosis, 797–798
management, 1148 arthroscopic/endoscopic lavage, etiology, 797
middle and proximal radius, fracture 1158–1159 osteoarthritis (OA), 797–798
management, 1147, 1149 lavage and drainage for synovial cavities, prognosis, 798
mid‐forelimb (mid‐metacarpus to distal 1158–1159 treatment, 798
radius), fracture management, through‐and‐through needle lavage, 1158 cervical fractures, 799
1146–1147, 1148 musculoskeletal system discospondylitis, 799
MMP (matrix metalloprotease) inhibition, magnetic resonance imaging (MRI), nuchal ligament, 796–797
laminitis treatment, 500 interpretation of MR images, 393–396 clinical signs, 796
mobilization, manual therapy, 926 nuclear medicine diagnosis, 796–797
MPA (methylprednisolone acetate), indications for nuclear medicine, 347–348 etiology, 796
intrasynovial therapies, 887–888 method for a scintigraphic exam, 344–347 prognosis, 797
MRI see magnetic resonance imaging ultrasonography indications, 332–334 treatment, 797
MSC (mesenchymal stem cell) therapy, musculoskeletal wound management, radiculopathy, 799
intralesional therapies, 896–897 1148–1149, 1151, 1152 neck palpation and manipulation, 115
MSCs (fat‐derived mesenchymal stem cells), preventing infection in traumatic wounds, neoplastic lesions, humerus, 637
intrasynovial therapies, 891 1148–1149, 1151, 1152 nerve blocks see anesthesia
MSM (methylsulfonylmethane), myelography, 195–198 neurological disease, 1177–1181
nutraceutical, 906 diagnosis, 1179, 1180
multiple cartilaginous exostosis, nail abscess, 1131 findings from a neurological exam that
osteochondroma (hereditary multiple naproxen see nonsteroidal anti‐inflammatory can help in localizing a lesion,
exostosis), 843–844 drugs 1178–1179
muscle disorders, 860–872 natural balance trimming and shoeing, head and body symmetry, 1178
classification, 860 1134–1142 level of consciousness and body position,
diagnosis of specific muscle disorders, see also therapeutic trimming and shoeing; 1178
860–862 trimming and shoeing manipulations in the standing horse,
ancillary diagnostic tests, 860–862 distortions of the hoof, 1134–1135 1178–1179
electromyography (EMG), 861 natural balance barefoot trimming, 1139 neurological gait and (neuroanatomical)
exercise response test, 861 natural balance evaluation, exfoliation, and lesion location, 1177–1178
genetic testing, 862 mapping protocol, 1135–1139 ataxia, 1177–1178
history, 860 exfoliating the foot, 1138 dysmetria, 1178
muscle biopsy, 861–862 mapping the foot, 1138–1139 weakness or paresis/paralysis, 1178
muscle enzymes, 860–861 recognizing hoof distortions, pitfalls of neurological examination, 1179,
physical examination, 860 1135–1138 1180
ultrasonography, 861 natural balance hoof care guidelines, 1135 select neurological syndromes affecting the
endurance horses, 1002–1003 natural balance shoeing, 1139–1142 gait, 1180–1181
exertional rhabdomyolysis (ER), navicular (distal sesamoid) botulism, 1180
865–872 fractures, 454–456 cervical vertebral stenotic myelopathy
chronic ER, 867, 870–872 clinical signs, 455 (CVSM), 1180
dietary imbalance, 866–867 diagnosis, 455 equine herpesvirus type 1‐associated
etiology, 866–867 etiology, 455 myeloencephalopathy (EHM), 1181
malignant hyperthermia, 867 prognosis, 456 equine motor neuron disease (EMND),
management of chronic forms of ER, treatment, 455–456 1180
870–872 navicular bone lesions, magnetic resonance equine protozoal myeloencephalitis
medications, 865–866 imaging (MRI), 401–402 (EPM), 1180–1181
myofibrillar myopathy (MFM), navicular bursa lesions, magnetic resonance ryegrass staggers, 1181
869–870 imaging (MRI), 403 shivers, 1181
polysaccharide storage myopathy navicular syndrome/disease stringhalt, 1181
(PSSM), 868–869 abnormalities, 439–440 West Nile virus and eastern/western/
recurrent ER, 867–868 clinical signs, 443–444 Venezuelan encephalitis viruses,
sporadic ER, 866 diagnosis, 444–448 1181
treatment of acute rhabdomyolysis, computed tomography (CT), 448 neuromuscular electrical stimulation
865–866 local anesthesia, 444–445 (NMES), rehabilitation/physical
vitamin E and selenium, 867 magnetic resonance imaging (MRI), 448 therapy, 940–941